IQV · XBRL financial data
Iqvia Holdings financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (IQV's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 3,868* | 3,737 | 3,814 | 3,896 | 3,958* | 3,829 | 4,017 | 4,100 | 4,364* | 4,151 | 4,368 | 4,428 |
| Gross profit | — | 827 | 863 | 915 | — | — | — | — | — | — | — | — |
| Selling, general and administrative | 556* | 508 | 509 | 522 | 453* | 508 | 509 | 514 | 468* | 502 | 574 | 569 |
| Operating income (loss) | 501* | 506 | 520 | 550 | 626* | 496 | 506 | 553 | 627* | 514 | 506 | 572 |
| Interest income | 12* | 11 | 12 | 13 | 11* | 11 | 10 | 13 | 11* | 10 | 7 | 12 |
| Interest expense | 181* | 166 | 163 | 170 | 171* | 165 | 182 | 189 | 193* | 192 | 197 | 203 |
| Other income (expense) | 47* | (11) | 67 | (44) | 78* | (15) | (11) | 31 | 94* | (4) | (12) | 5 |
| Income tax expense (benefit) | (102)* | 49 | 75 | 65 | 112* | 61 | 56 | 76 | 59* | 59 | 60 | 76 |
| Net income (loss) | 469* | 288 | 363 | 285 | 437* | 249 | 266 | 331 | 514* | 274 | 256 | 350 |
| Earnings per share, basic USD per share | 2.57* | 1.58 | 1.99 | 1.57 | 2.44* | 1.42 | 1.55 | 1.94 | 3.02* | 1.63 | 1.54 | 2.13 |
| Earnings per share, diluted USD per share | 2.54* | 1.56 | 1.97 | 1.55 | 2.42* | 1.40 | 1.54 | 1.93 | 2.99* | 1.61 | 1.53 | 2.10 |
| Weighted average shares, basic millions of shares | 182* | 182 | 182 | 182 | 179* | 176 | 172 | 170 | 170* | 168 | 166 | 165 |
| Weighted average shares, diluted millions of shares | 184* | 184 | 184 | 184 | 181* | 177 | 173 | 172 | 172* | 170 | 167 | 167 |
Balance sheet
CSVFiscal quarters (IQV's year ends in late December)
- ≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.
Cash flows
CSVFiscal quarters (IQV's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | 469* | 288 | 363 | 285 | 437* | 249 | 266 | 331 | 514* | 274 | 256 | 350 |
| Stock-based compensation | 45* | 56 | 48* | 54* | 48* | 72 | 60* | 55* | 60* | 65 | 95* | 83* |
| Depreciation and amortization | 316* | 264 | 269 | 278 | 303* | 265 | 276 | 286 | 317* | 288 | 292 | 321 |
| Net cash from operating activities | 747* | 522 | 588* | 721* | 885* | 568 | 443* | 908* | 735* | 618 | 558* | 825* |
| Net cash from investing activities | (212)* | (314) | (221)* | (599)* | (310)* | (305) | (346)* | (550)* | (1,104)* | (196) | (381)* | (559)* |
| Share repurchases | 229* | 0 | 0* | 200* | 1,150* | 375 | 657* | 0* | 212* | 552 | 398* | 0* |
| Net cash from financing activities | (420)* | (106) | (260)* | (137)* | (375)* | (258) | 145* | (572)* | 535* | (433) | (214)* | 78* |
| Net change in cash | 152* | 68 | 101* | 27* | 130* | 38 | 299* | (225)* | 166* | (33) | (38)* | 340* |
Compare with peers
SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Iqvia Holdings | 2,249 | 4,428 | 825* | 164.8M | 10-QSep 30, 2026 |
| Incyte | 3,276 | 1,557 | (675)* | 203.8M | 10-QSep 30, 2026 |
| Charles River Laboratories International | 200 | 983 | 254* | 47.9M | 10-QSep 26, 2026 |
| Medpace Holdings | 705 | 716 | 217* | 28.0M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.
